The other recognized favorable cytogenetic risk group is represented by CBF leukemias, including AML with t(8;21)(q22;q22) and inv(16)(p13.1q22) or t(16;16)(p13.1;q22), whose fusion products are RUNX1::RUNX1T1 and CBFB::MYH11, respectively [45,46]. Here, RUNX1 is linked to acute myeloid leukemia.